NEW STEP BY STEP MAP FOR TUSSILAGONE

Possible predictive biomarkers for tumor reaction to mTOR inhibitors, as have already been described in glioblastoma, breast and prostate most cancers cells, will be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[one] As a result, this details relies on preclinical assays, according to in vitro cultured tumor cell strains,